Navigation Links
Celecoxib may prevent lung cancer in former smokers
Date:7/5/2011

PHILADELPHIA Celecoxib may emerge as a potent chemopreventive agent for lung cancer, according to a recent study in Cancer Prevention Research, a journal of the American Association for Cancer Research.

Researchers tested celecoxib, a COX-2 inhibitor, among patients who were former smokers and found a significant benefit in bronchial health as measured by the Ki-67 labeling index, a marker of cellular proliferation or growth, as well as a number of other biomarkers. The findings follow a previous report published in Cancer Prevention Research that showed a similar effect on Ki-67 among former smokers and current smokers (Kim et al., Feb. 2010).

"Taken together, these findings strongly suggest that celecoxib can be used as a chemopreventive agent in these high-risk groups," said Jenny Mao, M.D., a professor of medicine at the University of New Mexico and section chief of pulmonary and critical care medicine at the New Mexico VA Health System.

Mao cautioned, however, that both the current study, where she was the lead researcher, and the Feb. 2010 study were phase II trials, and that large phase III trials are still needed to confirm the findings.

J. Jack Lee, Ph.D., a professor of biostatistics at The University of Texas M. D. Anderson Cancer Center and the statistical editor of Cancer Prevention Research, estimates that there are currently 45 million former smokers and 45 million current smokers in the United States alone.

"The oncology community does not have a good treatment for lung cancer. Unless it is caught in the earliest stages, the five-year survival is only about 15 percent," said Lee. "The best way is to intercept at the earliest stages and try to reverse the processes that can lead to cancer. These studies suggest celecoxib may be a tool to do that."

For the current study, Mao and colleagues enrolled 137 patients and randomly assigned them to 400 mg celecoxib twice daily or a p
'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study: Preventive use of one form of natural vitamin E may reduce stroke damage
2. Bone loss prevention experiment on the last space shuttle flight
3. Preventing diabetes damage: Zincs effects on a kinky, two-faced cohort
4. Alzheimers prevention in your pantry
5. Lithium profoundly prevents brain damage associated with Parkinsons disease
6. Using olive oil in your diet may prevent a stroke
7. USC: Active social, spiritual and physical life helps prevent health decline in seniors
8. Using magnets to help prevent heart attacks
9. Pregnant women can prevent excess weight gain with simple steps, study finds
10. Enzyme prevents fatal heart condition associated with athletes
11. UofL infection prevention and control expert to influence national health-care leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... alarming invasion of round goby into Great Lakes tributaries: ... A team of scientists from the University of Toronto, ... of Guelph has identified a drastic invasion of round ... of the Thames, Sydenham, Ausable and Grand Rivers. A ...
... awarded through federal stimulus research funding, a Kansas State ... eventually help diabetics preserve their eyesight. Dolores Takemoto, ... from the National Eye Institute to study how a ... protein kinase C gamma, called PKC gamma, and how ...
... , , , WALL, N.J., Aug. ... will be holding its second quarter conference call, which will be broadcast ... Eastern Time. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , ... International, Inc. Second Quarter 2009 Conference Call, When: ...
Cached Biology News:BIO-key(R) Announces Second Quarter Conference Call Schedule 2
(Date:11/26/2014)... and WILMINGTON, DE (PRWEB) November 26, 2014 ... Annual MPN Heroes recognition reception on December 5, 2014, ... Hematology’s annual meeting. The MPN Heroes event will honor ... in the field of myeloproliferative neoplasms (MPNs). , ... "Nashville," will discuss his family's cancer journey at the ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... NAMUR , Belgium , Nov. 24, ... life sciences company focused on developing diagnostic tests for cancer ... lung cancer study will be presented at the Science for ... Louvain-la-Neuve, Belgium . The data come from ... collected at the Pneumology department of the Centre Hospitalier Universitaire ...
Breaking Biology Technology:CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3IGI Laboratories, Inc. Announces ANDA Submission 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Aug. 22 DNA2.0,Inc. (http://www.DNA20.com ), ... and,Operon Biotechnologies (http://www.operon.com ), a leader ... a partnership to utilize their,synergistic technologies and ... production platform with DNA2.0,s,gene synthesis process, the ...
... 21 ,Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... (SAR) of a class of,internally-developed compounds that ... the company as potential treatments for irritable ... is currently,under evaluation in a Phase 1b ...
... Under Fire, WORCESTER, Mass., Aug. 21 ... proud to announced that Dr.,Robert Lanza, the company,s ... recognized for his research and contributions to stem,cell ... PharmaVOICE (cover,story July/August issue). Dr. Lanza is one ...
Cached Biology Technology:Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3
Human GATA-2 Affinity Purified Polyclonal Ab...
... microPET 120 utilizies CTI Molecular Imaging's proprietary ... same imaging volume as the R4. ... sensitivity of any commerically avaiable PET scanner. ... spatial resolution of any scinitallor based PETsystems. ...
... EVO series offers versatile liquid handling platforms ... a wide variety of life science applications.The ... base sizes (75, 100, 150 and 200 ... a platform that will advance with their ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: